Abstract
Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA(1c) were 114.9+/-20.6 kg, 10.3+/-2.1% at initiation; 108.0+/-15.3 kg (p<0.0001), 9.0+/-2.1% (p<0.001) at 3 months; 109.2+/-18.2 kg (p<0.0001), 9.5+/-2.3% (p=0.08) at 6 months. Exenatide appears effective in reducing HBA(1c) and weight.
(c) 2009 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
MeSH terms
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Body Mass Index
-
Body Weight
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Therapy, Combination
-
Exenatide
-
Glycated Hemoglobin / metabolism
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Insulin / therapeutic use
-
Peptides / therapeutic use*
-
Sulfonylurea Compounds / therapeutic use
-
Treatment Outcome
-
Venoms / therapeutic use*
-
Weight Loss
Substances
-
Blood Glucose
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Insulin
-
Peptides
-
Sulfonylurea Compounds
-
Venoms
-
Exenatide